-

ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, at 2:10 p.m. Eastern Time.

A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through April 2, 2020.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Contacts

Media Contact:
ACADIA Pharmaceuticals Inc.
Stephanie Fagan
(858) 212-0534
media@acadia-pharm.com

Investor Contact:
ACADIA Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Industry:

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD
Release Versions
English

Contacts

Media Contact:
ACADIA Pharmaceuticals Inc.
Stephanie Fagan
(858) 212-0534
media@acadia-pharm.com

Investor Contact:
ACADIA Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com

More News From ACADIA Pharmaceuticals Inc.

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad...

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q...

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live webcasts will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is commit...
Back to Newsroom